False myths and legends in laboratory diagnostics

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 11, 2013, Pages 2087-2097

  Lippi, Giuseppe ^a   Plebani, Mario ^b  

^a ACADEMIC HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

diagnostics; laboratory medicine; legends; myths; test

Indexed keywords

BENCE JONES PROTEIN; BIOLOGICAL MARKER; CINCHOCAINE; CONTRAST MEDIUM; D DIMER; ISCHEMIA MODIFIED ALBUMIN; LIPOPROTEIN A; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; POTASSIUM; PROSTATE SPECIFIC ANTIGEN; TROPONIN;

ACUTE KIDNEY FAILURE; BLEEDING; CANCER MORTALITY; DISEASE MARKER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGICAL PARAMETERS; HEMOLYSIS; HUMAN; HYPERKALEMIA; LABORATORY TEST; MORTALITY; MYSTICISM; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE VALUE; REVIEW; SCREENING TEST; THROMBOEMBOLISM;

CLINICAL LABORATORY TECHNIQUES; HUMANS; REFERENCE STANDARDS;

EID: 84886674988     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0105     Document Type: Review

References (96)

1. Plebani M. Lessons from controversy: Biomarkers evaluation. Clin Chem Lab Med 2013;51:247-8
2. Lippi G, Favaloro EJ, Franchini M. Laboratory diagnostics and therapy in thrombosis and hemostasis: From bedside to bench to bedside. Semin Thromb Hemost 2009;35:3-8
3. Lippi G, Favaloro EJ. Laboratory hemostasis: Milestones in clinical chemistry and laboratory medicine. Clin Chem Lab Med 2013;51:91-7
4. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: Causes and management. Blood Coagul Fibrinolysis 2010;21:459-63
5. Lippi G, Favaloro EJ. Activated partial thromboplastin time: New tricks for an old dogma. Semin Thromb Hemost 2008;34:604-11
6. Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost 2012;38:576-85
7. Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost 2012;38:565-75
8. Lippi G, Franchini M, Poli G, Salvagno GL, Montagnana M, Guidi GC. Is the activated partial thromboplastin time suitable to screen for von Willebrand factor deficiencies? Blood Coagul Fibrinolysis 2007;18:361-4
9. Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med 2007;45:2-12
10. Lippi G, Franchini M, Brazzarola P, Manzato F. Preoperative screening: The rationale of measuring APTT in risk assessment. Haematologica 2001;86:328
11. Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood 2012;120:4296-303
12. Cei M, Mumoli N, Giuntoli S, Marino O, Pasquinelli P, Taddei P, et al. Concomitant ST-elevation myocardial infarction and deep vein thrombosis in a patient with severe factor XII deficiency: Case report and review of the literature. Q J Med 2011;104:1083-6
13. Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012;38:375-84
14. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012;38:322-7
15. Lippi G, Favaloro EJ, Franchini M. Paradoxical thrombosis part 1: Factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT. J Thromb Thrombolysis 2012;34:360-6
16. Lippi G. Biomarkers of myocardial ischemia in the emergency room: Cardiospecific troponin and beyond. Eur J Intern Med 2013;24:97-9
17. Lippi G, Franchini M, Cervellin G. Diagnosis and management of ischemic heart disease. Semin Thromb Hemost 2013;39:202-13
18. Cardinaels EP, Mingels AM, Jacobs LH, Meex SJ, Bekers O, van Dieijen-Visser MP. A comprehensive review of upper reference limits reported for (high-)sensitivity cardiac troponin assays: The challenges that lie ahead. Clin Chem Lab Med 2012;50:791-806
19. Dimeski G, Jones B, Brown N. Carryover can be a cause of falsepositive results with the Beckman AccuTnI assay. Clin Chem Lab Med 2012;50:1135-6
20. Lippi G, Cervellin G. Degradation of troponin I in serum or plasma: Mechanisms, and analytical and clinical implications. Semin Thromb Hemost 2012;38:222-9
21. Lippi G, Avanzini P, Dipalo M, Aloe R, Cervellin G. Influence of hemolysis on troponin testing: Studies on Beckman Coulter UniCel Dxl 800 Accu-TnI and overview of the literature. Clin Chem Lab Med 2011;49:2097-100
22. Dimeski G. Evidence on the cause of false positive troponin I results with the Beckman AccuTnI method. Clin Chem Lab Med 2011;49:1079-80
23. Michielsen EC, Bisschops PG, Janssen MJ. False positive troponin result caused by a true macrotroponin. Clin Chem Lab Med 2011;49:923-5
24. Lackner KJ. Laboratory diagnostics of myocardial infarction-Troponins and beyond. Clin Chem Lab Med 2013;51:83-9
25. Lippi G, Cervellin G. Identification of troponin determinants for improving its diagnostic performance in the emergency department. J Emerg Med 2012;43:e487-8
26. Lippi G, Margapoti R, Aloe R, Cervellin G. Highly-sensitive troponin I in patients admitted to the emergency room with acute infections. Eur J Intern Med 2013 Feb 15. doi: 10.1016/ j.ejim.2013.01.019. [Epub ahead of print].
27. Lippi G, Dipalo M, Carbucicchio A, Aloe R, Benatti M, Cervellin G. The concentration of highly-sensitive troponin I is increased in patients with brain injury after mild head trauma. Int J Cardiol 2013 Feb 7. doi:10.1016/j.ijcard. 2013.01.018. [Epub ahead of print].
28. Lippi G, Cervellin G, Banfi G, Plebani M. Cardiac troponins and physical exercise. It's time to make a point. Biochem Med (Zagreb) 2011;21:55-62
29. Giannoni A, Giovannini S, Clerico A. Measurement of circulating concentrations of cardiac troponin I and T in healthy subjects: A tool for monitoring myocardial tissue renewal? Clin Chem Lab Med 2009;47:1167-77
30. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011;8:502-12
31. Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: An endogenous response to ischemia? Int J Cardiol 2006;108:410-1
32. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes-review and clinical implications. Clin Chem Lab Med 2011;49:177-84
33. Lippi G, Montagnana M. Ischemia-modified albumin in ischemic disorders. Ann Thorac Cardiovasc Surg 2009;15:137
34. Aslanand D, Apple FS. Ischemia modified albumin measured by the albumin cobalt binding test: A clinical and analytical review. Lab Medicine 2004;35:44-7
35. Lin S, Yokoyama H, Rac VE, Brooks SC. Novel biomarkers in diagnosing cardiac ischemia in the emergency department: A systematic review. Resuscitation 2012;83:684-91
36. Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia-modified albumin in routine clinical practice. Biomarkers 2010;15:655-62
37. Hakligör A, Kösem A, Seneş M, Yücel D. Effect of albumin concentration and serum matrix on ischemia-modified albumin. Clin Biochem 2010;43:345-8
38. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: Adjustment for serum albumin. Clin Chem Lab Med 2007;45:261-2
39. Hausen BS, Signor C, Kober H, Tatsch E, Pereira RS, Duarte T, et al. Effect of temperature on albumin cobalt binding and its influence on ischemia-modified albumin levels in patients with suspected acute coronary syndrome. Clin Lab 2012;58:169-72
40. Lippi G, Cervellin G, Franchini M, Favaloro EJ. Biochemical markers for the diagnosis of venous thromboembolism: The past, present and future. J Thromb Thrombolysis 2010;30: 459-71
41. Lippi G, Mengoni A, Manzato F. Plasma D-dimer in the diagnosis of deep vein thrombosis. J Am Med Assoc 1998;280:1828-9
42. Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, Doctor! My D-dimer is raised. Ann Med 2008;40:594-605
43. Lippi G, Favaloro EJ. D-dimer measurement and laboratory feedback. J Emerg Med 2009;37:82-3
44. Montagnana M, Cervellin G, Franchini M, Lippi G. Pathophysiology, clinics and diagnostics of non-Thrombotic pulmonary embolism. J Thromb Thrombolysis 2011;31:436-44
45. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
46. Brooks DD, Wolf A, Smith RA, Dash C, Guessous I. Prostate cancer screening 2010: Updated recommendations from the American Cancer Society. J Natl Med Assoc 2010;102:423-9
47. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71
48. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al European Association of Urology. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71
49. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2013;189(1 Suppl):S2-11
50. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13
51. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595-605
52. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 2012;366:981-90
53. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78
54. Filella X, Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: A systematic review and meta-Analysis. Clin Chem Lab Med 2013;51:729-39
55. Lippi G, Aloe R, Mattiuzzi C. Prostate-Specific Antigen (PSA) Isoform p2PSA in prostate cancer screening: Systematic review of current evidence and further perspectives. Riv Ital Med Lab 2012;8:231-8
56. Zambon CF, Prayer-Galetti T, Basso D, Padoan A, Rossi E, Secco S, et al. Effectiveness of the combined evaluation of KLK3 genetics and free-To-Total prostate specific antigen ratio for prostate cancer diagnosis. J Urol 2012;188:1124-30
57. Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficiency: A comprehensive review of genetic, acquired, and drug influences. AANA J 2010;78:313-20
58. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. Can J Biochem Physiol 1957;35:339-46
59. Lee C, Katz RL. Clinical implications of new neuromuscular concepts and agents: So long, neostigmine! So long, sux! J Crit Care 2009;24:43-9
60. Graziani M, Merlini G, Petrini C; for the IFCC Committee on Plasma Proteins and the SIBioC Study Group on Proteins Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003;41:338-46
61. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992;183:519-21
62. Lencioni R, Fattori R, Morana G, Stacul F. Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT)-A clinical problem in daily practice? A multicenter observational study. Acta Radiol 2010;51:741-50
63. Pahade JK, LeBedis CA, Raptopoulos VD, Avigan DE, Yam CS, Kruskal JB, et al. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. AJR Am J Roentgenol 2011;196: 1094-101
64. Thomsen HS; European Society of Urogenital Radiology. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007;17:70-6
65. Lippi G, Guidi G. Lipoprotein(a): An emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003;40:1-42
66. Lippi G, Franchini M, Targher G. Screening and therapeutic management of lipoprotein(a) excess: Review of the epidemiological evidence, guidelines and recommendations. Clin Chim Acta 2011;412:797-801
67. Berg K. Immunochemical studies of the Lp(a) factor. Acta Pathol Microbiol Scand 1964;62:600-12
68. Lippi G, Guidi G. Lipoprotein(a): From ancestral benefit to modern pathogen? Q J Med 2000;93:75-84
69. Lippi G, Targher G, Salvagno GL, Montagnana M, Franchini M, Guidi GC. Lipoprotein(a) and ageing. Clin Lab 2010;56: 463-6
70. Lippi G, Franchini M, Salvagno GL, Guidi GC. Lipoprotein[a] and cancer: Anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev 2007;33:427-36
71. Lippi G, Franchini M, Guidi GC. Lipoprotein(a), atherothrombosis and longevity. A historical paradox finally elucidated? Haematologica 2007;92:e48
72. Lippi G, Plebani M. Neutrophil gelatinase-Associated lipocalin (NGAL): The laboratory perspective. Clin Chem Lab Med 2012;50:1483-7
73. Lippi G, Aloe R, Storelli A, Cervellin G, Trenti T. Evaluation of NGAL Test™, a fully-Automated neutrophil gelatinase-Associated lipocalin (NGAL) immunoassay on Beckman Coulter AU 5822. Clin Chem Lab Med 2011;50:1581-4
74. Cavalier E, Bekaert AC, Carlisi A, Legrand D, Krzesinski JM, Delanaye P. Neutrophil gelatinase-Associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory's point of view. Clin Chem Lab Med 2011;49:339-41
75. Cervellin G, di Somma S. Neutrophil gelatinase-Associated lipocalin (NGAL): The clinician's perspective. Clin Chem Lab Med 2012;50:1489-93
76. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinaseassociated lipocalin (NGAL) as biomarker of acute kidney injury: A review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012;50:1505-17
77. Makris K, Rizos D, Kafkas N, Haliassos A. Neurophil gelatinaseassociated lipocalin as a new biomarker in laboratory medicine. Clin Chem Lab Med 2012;50:1519-32
78. Cruz DN, Gaiao S, Maisel A, Ronco C, Devarajan P. Neutrophil gelatinase-Associated lipocalin as a biomarker of cardiovascular disease: A systematic review. Clin Chem Lab Med 2012;50: 1533-45
79. Lippi G, Cervellin G. The predictive value of plasma neutrophil gelatinase-Associated lipocalin on cardiovascular death and all-cause mortality might be mediated by leukocytosis. J Am Coll Cardiol 2012;60:564
80. Lippi G, Caleffi A, Pipitone S, Elia G, Ngah A, Aloe R, et al. Assessment of neutrophil gelatinase-Associated lipocalin and lactate dehydrogenase in peritoneal fluids for the screening of bacterial peritonitis. Clin Chim Acta 2013;418C:59-62
81. Bolignano D. Serum creatinine and the search for new biomarkers of acute kidney injury (AKI): The story continues. Clin Chem Lab Med 2012;50:1495-9
82. Rastegar A. Serum potassium. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: The history, physical, and laboratory examinations. III ed. Boston: Butterworths, 1990:chapter 195
83. Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol 2011;26:377-84
84. Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: Historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med 2010;48:749-56
85. Lippi G, Becan-McBride K, Behúlová D, Bowen RA, Church S, Delanghe J, et al. Preanalytical quality improvement: In quality we trust. Clin Chem Lab Med 2013;51:229-41
86. Lippi G, Plebani M, Di Somma S, Cervellin G. Hemolyzed specimens: A major challenge for emergency departments and clinical laboratories. Crit Rev Clin Lab Sci 2011;48:143-53
87. Stankovic AK, Smith S. Elevated serum potassium values: The role of preanalytic variables. Am J Clin Pathol 2004;121(Suppl):S105-12
88. Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline, III ed. CLSI document C28-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008
89. Plebani M, Lippi G. Reference values and the journal: Why the past is now present. Clin Chem Lab Med 2012;50:761-3
90. Siest G, Henny J, Gräsbeck R, Wilding P, Petitclerc C, Queraltó JM, et al. The theory of reference values: An unfinished symphony. Clin Chem Lab Med 2013;51:47-64
91. Panteghini M, Ceriotti F. Obtaining reference intervals traceable to reference measurement systems: Is it possible, who is responsible, what is the strategy? Clin Chem Lab Med 2011;50:813-7
92. Ceriotti F. Common reference intervals: The IFCC position. Clin Biochem 2009;42:297
93. Ceriotti F. Establishing pediatric reference intervals: A challenging task. Clin Chem 2012;58:808-10
94. Fraser CG, Lippi G, Plebani M. Reference change values may need some improvement but are invaluable tools in laboratory medicine. Clin Chem Lab Med 2012;50:963-4
95. Fraser CG. Reference change values. Clin Chem Lab Med 2011;50:807-12
96. Cheuvront SN, Fraser CG, Kenefick RW, Ely BR, Sawka MN. Reference change values for monitoring dehydration. Clin Chem Lab Med 2011;49:1033-7